{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T23:02:48Z","timestamp":1772578968708,"version":"3.50.1"},"reference-count":22,"publisher":"Sociedad Espanola de Patologia Digestiva (SEPD)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Esp Enferm Dig"],"published-print":{"date-parts":[[2019]]},"DOI":"10.17235\/reed.2019.6152\/2018","type":"journal-article","created":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T11:06:11Z","timestamp":1560423971000},"source":"Crossref","is-referenced-by-count":14,"title":["The contribution of telemedicine to hepatitis C elimination in a correctional facility"],"prefix":"10.17235","volume":"111","author":[{"given":"Germ\u00e1n","family":"Jim\u00e9nez Gal\u00e1n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Alia Alia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milagros","family":"Vegue Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa M.\ufffd","family":"Garc\u00eda Berriguete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Fern\u00e1ndez Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Conrado M.","family":"Fern\u00e1ndez Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Gonz\u00e1lez Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Luisa","family":"Guti\u00e9rrez Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Emilio","family":"Losa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Velasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonor","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Herv\u00e1s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Delgado-Iribarren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregorio","family":"Palacios Garc\u00eda-Cervig\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6910","reference":[{"key":"ref1","unstructured":"1. Strategic Plan for Tackling Hepatitis C in the Spanish National Health System. Office of the Secretary for health and consumer affairs. http:\/\/www.easl.eu\/medias\/files\/eu\/PEAHC_v2_eng.pdf 1 Oct 2018"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.06.033"},{"key":"ref3","unstructured":"3. Astier Pe\u00f1a P, Divar Conde JM. Calidad Asistencial en la sanidad penitenciaria Espa\u00f1ola. Secretaria general de instituciones penitenciarias. Subdirecci\u00f3n general de coordinaci\u00f3n de sanidad penitenciaria. Ministerio del interior. Mayo 2010. http:\/\/www.institucionpenitenciaria.es\/web\/export\/sites\/default\/datos\/descargables\/bEpidemiologicos\/SACACOORDINACINONDESANIDAD9-4-10.pdf Accesed Dec 30th 2018."},{"key":"ref4","unstructured":"4. Ministerio de Interior \ufffd March 2017 data (www.institucionpenitenciaria.es); Comparecencia del Ministerio de Interior al Senado con el n\u00ba 15869 (13-1-2017)"},{"key":"ref5","unstructured":"5. Sanidad en prisi\u00f3n \ufffd APDHA; Tratamiento VHC en la poblaci\u00f3n reclusa, CIBERESP (Andr\u00e9s Marco); an\u00e1lisis IQVIA"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"6. Cuadrado A, Llerena S, Cobo C, Pall\u00e1s JR, Mateo M, Cabezas J et al Microenvironment Eradication of Hepatitis C: A Novel Treatment Paradigm Am J Gastroenterol 2018;113:1639-1648","DOI":"10.1038\/s41395-018-0157-x"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-011-1166-5"},{"key":"ref8","unstructured":"8. WHO. Combating hepatitis B and C to reach elimination by 2030 Advocacy brief"},{"key":"ref9","unstructured":"https:\/\/www.who.int\/hepatitis\/publications\/hep-elimination-by-2030-brief\/en\/"},{"key":"ref10","unstructured":"Accesed on Dec 30, 2018."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13008. [Epub ahead of print] PubMed PMID: 30265418"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12637. Epub 2016 Dec 15. PubMed PMID: 27976491"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12648"},{"key":"ref14","unstructured":"12. Llaneras J, Riveiro-Barciela M, Esteban R et al. Real-life effectiveness and safety of velpatasvir\/sofosbuvir\/voxilaprevir for previously DAA treated patients with chronic hepatitis C The Liver Meeting (AASLD), San Francisco, United States. 9th November 2018"},{"key":"ref15","unstructured":"13. Puigvehi M, Albillos A, Viu A et al. Effectiveness and Safety of Glecaprevir\/Pibrentasvir for the Pangenotypic Treatment of Chronic Hepatitis C: Results from a Spanish Cohort (Hepa-C) The Liver Meeting (AASLD) ,San Francisco, United States. 9th November 2018"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"14. Brown R, Hezode Ch, Wang S, Buti M, Chuang WL, Aguilar H et al. Preliminary efficacy and safety of 8-weeks Glecaprevir\/Pibrentasvir in patients with HCV genotype 1-6 infection and compensated cirrhosis: The expedition-8 Study. AASLD-2018","DOI":"10.1016\/j.jhep.2019.10.020"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"15. Calleja JL , Crespo J , Rinc\u00f3n D et al. The Spanish Group for the Study of the Use of Direct-acting Drugs Hepatitis C Collaborating Group Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort, J Hepatol 2017; 66: 1138\ufffd114","DOI":"10.1016\/j.jhep.2017.01.028"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13017. [Epub ahead of print]"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1228"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"18. Turnes J, Dom\u00ednguez-Hern\u00e1ndez R, Casado M\u00c1 Value and innovation of direct-acting antivirals: long-term health outcomes of the strategic plan for the management of hepatitis C in Spain Rev Esp Enferm Dig. 2017;109:809-817.","DOI":"10.17235\/reed.2017.5063\/2017"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"19. Go\u00f1i Esarte S, Juanbeltz R, Mart\u00ednez-Baz I, Castilla Catal\u00e1n J, San Miguel R, Herrero Santos JI, Jose Manuel Zozaya JM Long-term changes on health related quality of life in patients with chronic hepatitis C after viral clearance with direct-acting antiviral agents. Rev Esp Enf Dig 2019 In press","DOI":"10.17235\/reed.2019.6063\/2018"},{"key":"ref22","unstructured":"20. Pontali E, Fiore V, Ialungo AM, Ranieri R, Mollaretti O, Barbarini G, Marri D, Prestileo T, Dell'Isola S, Rastrelli E, Leo G, Starnini G, Babudieri S, Madeddu G. Treatment with direct-acting antivirals in a multicenter cohort of HCV-infected inmates in Italy Int J Drug Policy. 2018; 59:50-53."}],"container-title":["Revista Espa\u00f1ola de Enfermedades Digestivas"],"original-title":[],"deposited":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T19:48:14Z","timestamp":1574970494000},"score":1,"resource":{"primary":{"URL":"https:\/\/online.reed.es\/fichaArticulo.aspx?iarf=730790158349-588165823257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":22,"URL":"https:\/\/doi.org\/10.17235\/reed.2019.6152\/2018","relation":{},"ISSN":["1130-0108"],"issn-type":[{"value":"1130-0108","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}